By demonstrating that dual-acting gene therapy targeting VEGFA delivered by multigenic AAV vectors evidently provides combined efficacy, we believe that multigenic AAV vectors may be an important tool in the future treatment of neovascular diseases of the retina, including AMD. Here, VEGFA is linked to age-related macular degeneration.